<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95892">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02065856</url>
  </required_header>
  <id_info>
    <org_study_id>2013-001728-20</org_study_id>
    <secondary_id>2013-001728-20</secondary_id>
    <nct_id>NCT02065856</nct_id>
  </id_info>
  <brief_title>An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy</brief_title>
  <acronym>AV-X-02</acronym>
  <official_title>An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is an open, national, multi-centre trial. The trial will be initiated in December
      2013 and subjects will receive treatment for 6 weeks.

      Safety monitoring will be performed in an ongoing basis through a Clinical Safety Group with
      immediate access to AEs registered in the clinical database. The composition, procedures and
      deliverables of the Clinical Safety Group will be detailed in a Safety Agreement prior to
      trial start.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Frequency of patientes with adverse reactions</measure>
    <time_frame>Participants will be followed for an expected average of 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of patients with systemic reactions according to  EAACI classification</measure>
    <time_frame>Participants will be followed for an expected average of 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen</condition>
  <arm_group>
    <arm_group_label>AVANZ Salsola kali</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVANZ Salsola kali</intervention_name>
    <arm_group_label>AVANZ Salsola kali</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical history of  Salsola kali pollen induced allergic rhinoconjunctivitis with
             or without asthma at least one year prior to trial entry.

          -  Positive SPT to  Salsola kali pollen (wheal diameter ≥ 3 mm).

          -  Documenting in the last 5 years a positive specific IgE against  Salsola kali pollen
             (≥ Class 2; ≥0.70 KU/L).

        Exclusion Criteria:

          -  FEV1 &lt; 70% of predicted value at screening after adequate pharmacologic treatment.

          -  Uncontrolled or severe asthma.

          -  History of severe asthma exacerbation  or emergency room visit or admission for
             asthma in the previous 12 months.

          -  At screening, current symptoms of, or treatment for, upper respiratory tract
             infection, acute sinusitis, acute otitis media or other relevant infection (serous
             otitis media is not an exclusion criterion).

          -  Treatment with parenteral corticosteroids, oral corticosteroids or anti-IgE in the
             previous 3 months or during the study (except for steroids if needed as rescue
             medication).

          -  Currently treated with angiotensin converting enzyme (ACE) inhibitors, tricyclic
             antidepressants, β-blockers, mono amine oxidase inhibitors (MAOIs) and any other drug
             containing alum (e.g. antacids) taken on a daily basis.

          -  Immunotherapy with Cupressus arizonica or Salsola kali pollen extracts within the
             previous 5 years (initiation of subcutaneous immunotherapy is acceptable if treatment
             has been discontinued before reaching maintenance dose; for SLIT 3 months in the last
             5 years is accepted) or concomitant immunotherapy with any other allergen.

          -  History of anaphylactic shock due to e.g. food, insect venom, exercise or drug.

          -  History of severe and recurrent angioedema.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PURIFICACION GONZÁLEZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SANTIAGO MARTIN, MsC</last_name>
    <phone>+34913276127</phone>
    <email>SMAES@ALK.NET</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PILAR RICO, PhD</last_name>
    <phone>+34913276127</phone>
    <email>PRNES@alk.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PURIFICACIÓN GONZÁLEZ, PhD</last_name>
      <email>gonzalez_pur@gva.es</email>
    </contact>
    <investigator>
      <last_name>PURIFICACIÓN GONZÁLEZ, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>January 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
